332394-37-3

Basic information

• Product Name: (3,5-DIMETHOXYPHENYL)METHANOL-4-BORONIC ACID
• Synonyms: (3,5-DIMETHOXYPHENYL)METHANOL-4-BORONIC ACID
• CAS NO: 332394-37-3
• Molecular Formula: C₉H₁₃BO₅
• Molecular Weight: 0
• Mol File: 332394-37-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3,5-DIMETHOXYPHENYL)METHANOL-4-BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (3,5-DIMETHOXYPHENYL)METHANOL-4-BORONIC ACID(332394-37-3)
• EPA Substance Registry System: (3,5-DIMETHOXYPHENYL)METHANOL-4-BORONIC ACID(332394-37-3)

Safety Data

• Hazardous Substances Data: 332394-37-3(Hazardous Substances Data)

Upstream product

• 1144100-27-5 C₂₀H₃₃BO₆ 
• 1144100-26-4 {4-[(1-isopropoxyethoxy)methyl]-2,6-dimethoxyphenyl}boronic acid 
• 1144100-24-2 {2,6-dimethoxy-4-[(1-propoxyethoxy)methyl]phenyl}boronic acid 
• 1144100-22-0 {4-[(1-ethoxyethoxy)methyl]-2,6-dimethoxyphenyl}boronic acid 
• 121-43-7 Trimethyl borate 
• 705-76-0 3,5-dimethoxybenzyl alcohol 

Downstream Products

• 685885-79-4 [4-(3-{(cyclopropylmethyl)[(tetrahydro-2H-pyran-4-yl)-methyl]amino}-2-ethylpyrazolo[1,5-a]pyridin-7-yl)-3,5-dimethoxyphenyl]methanol 

Relevant articles and documents

METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE

Disclosed is a commercially advantageous method for producing a pyrazole fused ring derivative (such as a 7-phenylpyrazolo[1,5-a]pyridine derivative). Specifically disclosed is a method for producing a compound (I) represented by the formula (I) below or a salt thereof, which comprises a step A wherein a hydroxy group in a compound (IV) represented by the formula (IV) below is converted into a methoxy group, thereby obtaining a compound (I) or a salt thereof:

NOVEL COMPOUNDS

The present invention relates to novel phenylalanine compounds, processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.

7-phenylpyrazolopyridine compounds

A compound represented by the formula: [wherein R1 is methoxy, methylthio, ethyl, etc.; R5 and R6 are each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R40, R41 and R42 are C1-6 alkoxy while the remaining one is methoxymethyl, etc.], a salt thereof, or a hydrate of the foregoing. This compound has excellent antagonism against corticotropin-releasing factor receptor.

Inhibitors of α4 mediated cell adhesion

The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, —O-(lower alkylene)-, etc.; n is 0, 1 or 2; Z is oxygen or sulfur, W is oxygen, sulfur, —CH═CH—, —NH— or —N═CH—; R1, R2and R3are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, etc.; R4is tetrazolyl, carboxyl group, amide or ester; R5is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl etc.; R6is selected from (a) a substituted or unsubstituted phenyl group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof.